Literature DB >> 8394077

Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II.

L A Zwelling1, J Mayes, E Altschuler, P Satitpunwaycha, T R Tritton, M P Hacker.   

Abstract

We have examined the activities of two novel aza-anthracene-9,10-diones (aza), 1-aza and 2-aza, in HL-60 human leukemia cell lines containing type II topoisomerases with different sensitivities to inhibition by other intercalating agents. The sensitive line, HL-60, was sensitive to 2-aza but not to 1-aza, whereas the resistant HL-60/AMSA was sensitive to neither agent. Measurements of 1- and 2-aza-induced, topoisomerase II-mediated DNA cross-linking in the cells revealed patterns of resistance and sensitivity that paralleled the results in the cytotoxicity assays. However, measurements of drug-induced topoisomerase II-mediated DNA cross-linking using purified HL-60 and HL-60/AMSA topoisomerase II indicated that both agents could stabilize a covalent complex between DNA and the HL-60 enzyme. HL-60/AMSA topoisomerase II resisted stabilization by either agent. This suggests that the resistance of HL-60 cells to 1-aza is not due to the inability of this drug to inhibit topoisomerase II but rather to another, undefined mechanism.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8394077     DOI: 10.1016/0006-2952(93)90413-q

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing program.

Authors:  Raushan T Kurmasheva; C Patrick Reynolds; Min H Kang; Cecilia Allievi; Peter J Houghton; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2013-10-26       Impact factor: 3.167

2.  Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.

Authors:  Brian B Hasinoff; Xing Wu; Daywin Patel; Ragu Kanagasabai; Soumendrakrishna Karmahapatra; Jack C Yalowich
Journal:  J Pharmacol Exp Ther       Date:  2015-12-11       Impact factor: 4.030

Review 3.  Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.

Authors:  Stefano Volpetti; Francesco Zaja; Renato Fanin
Journal:  Onco Targets Ther       Date:  2014-05-29       Impact factor: 4.147

4.  CpG methylation potentiates pixantrone and doxorubicin-induced DNA damage and is a marker of drug sensitivity.

Authors:  Benny J Evison; Rebecca A Bilardi; Francis C K Chiu; Gabriella Pezzoni; Don R Phillips; Suzanne M Cutts
Journal:  Nucleic Acids Res       Date:  2009-08-31       Impact factor: 16.971

5.  Pixantrone can be activated by formaldehyde to generate a potent DNA adduct forming agent.

Authors:  Ben J Evison; Oula C Mansour; Ernesto Menta; Don R Phillips; Suzanne M Cutts
Journal:  Nucleic Acids Res       Date:  2007-05-05       Impact factor: 16.971

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.